Open Access

LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway

  • Authors:
    • Xiaomei Sui
    • Yana Sui
    • Yonghui Wang
  • View Affiliations

  • Published online on: April 5, 2018     https://doi.org/10.3892/mmr.2018.8856
  • Pages: 7521-7528
  • Copyright: © Sui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The incidence of thyroid cancer has increased the past few decades, the most frequent type has been identified to be the papillary thyroid carcinoma (PTC). Following thyroidectomy, radioiodine ablation treatment on PTC is routinely performed. However, many patients do not benefit from radioiodine therapy. Therefore, novel targeted therapies to suppress tumor growth and improve radioiodine uptake are required. La ribonucleoprotein domain family member (LARP)7 is a member of the LARP family and functions as a potential suppressor of the progression of carcinoma. In the present study, the expression status of LARP7 in PTC tissues and cell lines was investigated, and the cell viability, proliferation and apoptotic rate, radioiodine uptake ability of PTC cells with overexpression of LARP7 in vitro was determined. Expression levels of LARP7 were significantly downregulated in PTC tissues and cell lines. Overexpression of LARP7 inhibited the proliferation and increased the radioiodine uptake ability of PTC cells in vitro and inhibited the tumor growth in vivo. Furthermore, LARP7 overexpression inhibited the sonic hedgehog (SHH) signaling pathway and increased sodium/iodide symporter (NIS) expression. However, treatment with recombinant human SHH partially reduced radioiodine uptake ability and NIS expression induced by LARP7. In conclusion, LARP7 may act as a tumor suppressor in PTC by inhibiting the SHH signaling pathway and may be a promising therapeutic target in patients with PTC.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 17 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sui X, Sui Y and Wang Y: LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway. Mol Med Rep 17: 7521-7528, 2018
APA
Sui, X., Sui, Y., & Wang, Y. (2018). LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway. Molecular Medicine Reports, 17, 7521-7528. https://doi.org/10.3892/mmr.2018.8856
MLA
Sui, X., Sui, Y., Wang, Y."LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway". Molecular Medicine Reports 17.6 (2018): 7521-7528.
Chicago
Sui, X., Sui, Y., Wang, Y."LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway". Molecular Medicine Reports 17, no. 6 (2018): 7521-7528. https://doi.org/10.3892/mmr.2018.8856